Reports Archive   Year   
Date Title Pages Source Download
Oct-20 September sees strong recovery in IPM   26 Motilal Oswal
Oct-20 Lockdown savings to aid margins   6 Edelweiss Securities
Oct-20 Scenario Analysis for Large cap Pharma – FY21E-24E   51 Nirmal Bang
Sep-20 Cardiac: the heartbeat of domestic market   28 HDFC Securities
Sep-20 Perrigo's exit from Albuterol provides interesting short-term opportunity   4 Emkay Research
Sep-20 Slow healing to normalcy in India/EMs   20 Motilal Oswal
Sep-20 Unlock 3.0 grapples to sustain IPM growth   13 Prabhudas Lilladher
Sep-20 IPM declines in Aug’20 after posting muted growth in Jul'20   26 Motilal Oswal
Sep-20 Withdrawal of MEIS impact may be severe if prolonged   5 Prabhudas Lilladher
Aug-20 July growth tapers down to 0.9%   15 Emkay Research
Aug-20 Chronic therapies perform better than Acute   26 Motilal Oswal
Jul-20 Our initial reading of Trump's executive order on drugs   4 Emkay Research
Jul-20 Chronic therapy: A portfolio prescription   15 HDFC Securities
Jul-20 IPM growth reprises positive territory, industry grows 2.4% in Jun   27 Anand Rathi
Jul-20 Raising red flag over Global Fund & Institutional drug suppliers amid COVID-19   15 Prabhudas Lilladher
Jul-20 India Pharma: Q1 FY21 Preview   30 Anand Rathi
Jul-20 IPM growth recovers from April/May lows   15 Emkay Research
Jul-20 Lockdown, high base to weigh; currency to support   5 ICICI
Jul-20 IPM in recovery mode led by price hikes   26 Motilal Oswal
Jul-20 Q1 Preview: Down, but not out   14 Emkay Research
Jul-20 Apr-Jun'20 Earnings Preview   7 Prabhudas Lilladher
Jul-20 Pharma Tablet   10 Motilal Oswal
Jun-20 All indicators point in one direction   15 IIFL
Jun-20 IPM: Declining trend maintains on extended lockdown   13 Prabhudas Lilladher
Jun-20 IPM on the decline in May’20 as well, but gradual recovery visible   26 Motilal Oswal
May-20 Labs with home pick-up model at advantage   5 Emkay Research
May-20 Pharma- On road to recovery   15 Edelweiss Securities
May-20 Growth takes a back seat due to Covid-19   14 Emkay Research
May-20 COVID-19-led contraction in acute therapies impacts IPM's performance   26 Motilal Oswal
May-20 FDA issues EUA to Gilead's Remdesivir for COVID-19 treatment   5 Prabhudas Lilladher
Apr-20 Target valuation multiple revision   19 Nirmal Bang
Apr-20 India Pharma: Q4 FY20 Preview   35 Anand Rathi
Apr-20 Target valuation multiple revision   19 Nirmal Bang
Apr-20 Pharma stocks poised for re-rating amid panic   15 ICICI
Apr-20 Anticipating a gradual resumption   13 IIFL
Apr-20 Remdesivir – Expectation outweigh the facts from a small trial   5 Prabhudas Lilladher
Apr-20 Sector in fad mode ; panic buying not backed by persistent earnings   15 Prabhudas Lilladher
Apr-20 Q4 Preview: A moderate quarter   14 Emkay Research
Apr-20 Interview with API industry veteran   3 Nirmal Bang
Apr-20 Navigating well in turbulent waters   33 Emkay Research
Apr-20 Indian Pharma: Flight to Safety   8 HDFC Securities
Apr-20 No significant Covid 19 impact expected   5 ICICI
Apr-20 Undone by pandemic panic; valuations compelling   9 ICICI
Mar-20 Key prescription trends this quarter   11 Nirmal Bang
Mar-20 Volume growth revives; Sustainability remains key monitorable   26 Motilal Oswal
Mar-20 IPM growth not yet impacted by Covid-19   10 Prabhudas Lilladher
Mar-20 Drugs and Pharma Update: February 2020   3 CARE Research
Feb-20 Volumes continue impacting overall growth   26 Motilal Oswal
Feb-20 Robust India drives Q3   6 HDFC Securities
Feb-20 DOJ’s new indictments, negative for Taro   5 IIFL
Feb-20 Domestic drives Q3; Aurobindo Unit IV receives VAI   16 ICICI
Feb-20 Cost rationalization remains the key for FY21   10 Emkay Research
Jan-20 Tepid volumes drag overall growth in Dec'19   26 Motilal Oswal
Jan-20 Sequentially weak profitability as compliance issues pile up   7 Ashika Stock Broking
Jan-20 Dec'19 IPM growth in line with expectations   10 Emkay Research
Jan-20 Q3 FY20 Preview   32 Anand Rathi
Jan-20 Tepid earnings growth; valuations buoyant   8 Edelweiss Securities
Jan-20 Steady Quarter   7 Centrum Research
Jan-20 Base business strengthening – Earnings continue to be range bound   4 Nirmal Bang